



Express Mail No.: EV 452 775 577 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Satoh et al.

Confirmation No.: 6771

Application No.: 10/004,645

Group Art Unit: 1617

Filed: December 4, 2001

Examiner: J. Kim

For: ANILINOPYRIMIDINE
DERIVATIVES AS JNK
INHIBITORS AND
COMPOSITIONS AND
METHODS RELATED THERETO

Attorney Docket No.: 10624-050-999
CAM: 700755-999049

THIRD SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or might be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **DG-DO**, which are listed on the accompanying revised Form PTO-1449 entitled "List of References Cited By Applicant."

A copy of references **DG-DO** are enclosed herein.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review references **DG-DO** identified on the attached Form PTO-1449 and make them of record in the file history of the above-identified application by initializing the attached Form PTO-1449.

As this Information Disclosure Statement is being submitted before the mailing of any final action under § 1.113, a notice of allowance under § 1.311, or an action that

otherwise closes prosecution in the application, it is estimated that a fee of \$180.00 is due pursuant to 37 C.F.R. §§ 1.97(c)(2) and 1.17(p). Please charge the required fee to Jones Day Deposit Account No. 50-3013. Should the Patent and Trademark Office determine that any additional fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this document is enclosed for accounting purposes.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

Date June 24, 2005

By: Michael J. Bruner, Reg. No. 47,458

By: Michael J. Bruner (Reg. No. 47,458)
For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1130



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 10624-050-999 (CAM #700755-999049)	APPLICATION NO 10/004,645
	APPLICANT Satoh <i>et al.</i>	
	FILING DATE December 4, 2001	GROUP 1617

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
					YES	NO	
DG	WO 02/20512	3/14/02	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)	
DH	Bennett <i>et al.</i> , "SP600125, an anthrapyrazole inhibitor of Jun N-terminal kinase," <i>P.N.A.S.</i> 98(24):13681-13686 (2001).
DI	Downey, <i>et al.</i> , "Cellular Activation Mechanisms in Septic Shock," <i>Frontiers in Bioscience</i> 3:468-476 (1998).
DJ	Haunstetter, <i>et al.</i> , "Apoptosis - Basic Mechanisms and Implications for Cardiovascular Disease," <i>Circ. Res.</i> 82:1111-1129 (1998).
DK	Hreniuk, <i>et al.</i> , "Inhibition of C-Jun N-Terminal Kinase 1, but Not c-Jun N-Terminal Kinase 2, Suppression Apoptosis Induced by Ischemia/Reoxygenation in Rat Cardiac Myocytes," <i>Molecular Pharmacology</i> 59(4):867-874 (2001).
DL	Izumi, <i>et al.</i> , "Important Role of Angiotensin II-Mediated c-Jun NH ₂ -Terminal Kinase Activation in Cardiac Hypertrophy in Hypertensive Rats," <i>Hypertension</i> 36:511-516 (2000).
DM	Kim, <i>et al.</i> , "Stress and Vascular Responses: Mitogen-Activated Protein Kinases and Activator Protein-1 as Promising Therapeutic Targets of Vascular Remodeling," <i>J. Pharmacol. Sci.</i> 91:177-181 (2003).
DN	Purves, <i>et al.</i> , "A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy," <i>FASEB</i> 15:2508-2514 (2001).
DO	Srivastava, <i>et al.</i> , "Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD," <i>J. Clin. Invest.</i> 104(4):503-513 (1999).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	